Navigation Links
New Method For Measuring Dyskinesia In Parkinson's Being Developed

The first scale to measure the presence and severity of involuntary, uncontrolled movements called dyskinesia in Parkinson's disease is being developed// and a couple of neurologists have been granted $134,000 by the Michael J. Fox Foundation for this purpose.

“The development of a Unified Dyskinesia Rating Scale will provide a critical research tool for any future clinical trial,” says Dr. Christopher G. Goetz, Director of Movement Disorders of Rush University Medical Center, who along with Dr. John G. Nutt, Oregon Health and ScienceUniversity, are working to develop the rating scale.

Goetz says that without a comprehensive scale, current clinical trials make use of many disparate scales that rely on different types of clinical assessments. “The lack of a Unified Dyskinesia Rating Scale makes it difficult to compare results across research studies and decreases the robustness of clinical trials testing dyskinesia treatments.”

When it comes to measuring a new therapy’s effects on dyskinesias — the involuntary, uncontrollable, and excessive movements that are a common side effect of drugs used to treat Parkinson’s Disease— different clinicians observing the same evidence can potentially come to very different conclusions. No standardized and comprehensive tool exists to make the judgment easier.

“Dyskinesias have such a large impact on patients’ day-to-day lives that nearly every Parkinson’s clinical trial measures them — even trials that don't explicitly involve a dyskinesia therapy,” said Katie Hood, the Michael J. Fox Foundation’s (MJFF) vice president of research programs, one of the two research funding agencies. “But the resulting body of evidence lacks cohesion because there is no common set of metrics for reporting on dyskinesias. Practitioners agree on the strong need for a ‘common language’ if we are to successfully address this difficult complication of Parkinson’s treatment.”

Dyskinesiascan be lurching, dance-like or jerky and are distinct from the rhythmic tremor commonly associated with Parkinson’s DISEASE.. Hood says they are a research priority for the MJFF because patients often cite them as one of the most disabling aspects of living with the disease.

Goetz and Nutt have already consolidated elements of existing dyskinesia scales into a working draft of the unified scale. Funding from the MJFF will allow this draft to be finalized, tested and presented to the movement disorder community.

The validation studies will be done in several steps. The researchers must first test the consistency and reliability of the scale. To do this, they will videotape examinations of about 70 Parkinson’s patients with varying dyskinesia severity levels. The videotapes will be distributed to clinician raters along with a preliminary version of the scale, which the clinicians will use to rate the taped patients’ dyskinesias. Goetz and Nutt will look for variations in the raters’ scores on these identical cases to refine the scale and the instructions for using it.

The physicians will then prepare a teaching tape for widespread distribution to clinicians.

The teaching tape will include segments featuring at least four patients at each level of dyskinesia severity. The teaching tape will have an “answer key” — ratings made by three internationally recognized dyskinesia experts. Clinicians learning to use the scale will be able to watch the tape, make their own assessments, and then compare their ratings to the experts’. The researchers plan to present the Unified Dyskinesia Rating Scale, together with all instructions and teaching tools for its use, to the movement disorder community by early 2008. The Michael J. Fox Foundation (MJFF) has awarded the researchers $84,000 and EMD Pharmaceutic has given $50,000 in funding. Contact: Mary Ann Schultz mary_ann_schultz@rush.edu 312-942-7816 Rush University Medical Cnter Sou rce: Eurekalert
'"/>




Related medicine news :

1. Methods to have a flat stomach
2. Easier Methods Required to Screen Insulin Resistance
3. Easier Methods Required to Screen Insulin Resistance
4. Accuracy of Some Natural Family Planning Methods Questioned .
5. New Method Of Delivering Chemotherapy
6. Adopting Easier Methods To Screen Insulin Resistance
7. Diagnosing Sleep Apnea By Overnight Sleep Testing Method
8. New Screening Method Found To Detect Testicular Cancer In Its Initial Stages
9. A Novel Method For Measuring Interstitial Fluid Pressure In Cancer Tissues
10. A Novel Method Of Detection Of High Nuclear Grade Localized Renal Cell Carcinoma
11. New Method To Identify Protein Hot spots
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/28/2017)... ... March 28, 2017 , ... ... Camp Conference in Atlantic City March 13-16, was a busy spot this year. ... professional staff discussed strategies for preventing outbreaks among camp communities during the upcoming ...
(Date:3/28/2017)... ... ... skin is a common and unwelcomed occurrence in people of all ages, genders and ethnicities. ... the discussion of dealing with excess skin oil. “Oily skin is a challenge to many ... help remove the oily shine while keeping the skin fresh and clean,” says Dr. Au. ...
(Date:3/28/2017)... ... ... Prophets Bones”: a thrilling adventure that reveals the mystery of Kevin’s purpose. “A Prophets Bones” ... and teachers had asked of him that he had neglected to do, but this was ... Creator. There were some who would have felt themselves to be special and better than ...
(Date:3/27/2017)... Clearwater, FL (PRWEB) , ... March 27, 2017 ... ... accepts new patients for clear braces. People who want straight teeth without the ... Invisalign® in Clearwater, FL, without acquiring a referral. A custom-designed series ...
(Date:3/27/2017)... ... March 27, 2017 , ... Drs. Justin Kolnick, Kara Diamond, Randall Barton, ... patients about the key role this treatment plays in protecting oral health, along with ... better serve those who need a root canal in White Plains, NY or their ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... , March 27, 2017   Pulmatrix, Inc . (NASDAQ: ... to address serious pulmonary diseases, today announced that it has ... cystic fibrosis and asthma to its Scientific Advisory Board ... Richard B. Moss , MD, former chief of ... the Cystic Fibrosis Center at Stanford University, and ...
(Date:3/27/2017)... , March 27, 2017 On ... the NASDAQ Composite closed the trading session up 0.19%; ... the S&P 500 was down 0.08%. US markets made ... finishing the day in green. Pre-market today, Stock-Callers.com reviews ... Group N.V. (NASDAQ: WMGI), Amedica Corporation (NASDAQ: AMDA), MiMedx ...
(Date:3/27/2017)... March 27, 2017  Impax Laboratories, Inc. (NASDAQ: IPXL)today ... Paul M. Bisaro as Impax,s President and Chief ... effective March 27, 2017. Mr. Bisaro will succeed ... President and Chief Executive Officer since December of 2016. ... branded pharmaceutical experience, Mr. Bisaro, 56, is an accomplished ...
Breaking Medicine Technology: